Status:
COMPLETED
Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
Lead Sponsor:
Pfizer
Conditions:
Acromegaly
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Detailed Description
All the patients whom an investigator prescribes the first Somavert (Pegvisomant) should be registered consecutively until the number of subjects reaches target number in order to extract patients enr...
Eligibility Criteria
Inclusion
- Patients need to be administered Somavert (Pegvisomant) in order to be enrolled in the surveillance.
Exclusion
- Patients not administered Somavert (Pegvisomant).
Key Trial Info
Start Date :
August 7 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2016
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT00658879
Start Date
August 7 2007
End Date
November 9 2016
Last Update
September 25 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.